http://happyandhealthyover40.com/relieving-suffering-emerging-bio-technology/
http://happyandhealthyover40.com/relieving-suffering-emerging-bio-technology/
Category: aging
According to a French physiologist, humans have reached the peak of our height, lifespan and physical fitness.
I suspect that from our vantage point (a narrow snapshot of human evolution), we lack sufficient data to arrive this sweeping conclusion. Nevertheless, mainstream media is taking this research seriously.
http://www.newsweek.com/humans-reached-peak-height-lifespan-fitness-741816
In Unexpected Futurist, we profile the lesser known futurist side of influential individuals. This episode’s unexpected time-traveler: Benjamin Franklin. Ben Franklin was an inventor, observer, electricity pioneer, and serial experimenter, so it’s not entirely surprising he looked to the future. But it turns out he was looking to the far, far future. In 1780 he wrote a letter to a friend in which he lamented that he was born during the dawn of science.
Bioquark Inc. and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement
Posted in aging, bioengineering, biotech/medical, disruptive technology, DNA, genetics, health, life extension, posthumanism, science | Leave a Comment on Bioquark Inc. and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement
Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, and Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, announced a multi-disciplinary research collaboration with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences (http://www.academpharm.ru/), and the Pavlov Institute of Physiology of the Russian Academy of Sciences (http://www.infran.ru/), to jointly study the pharmacotherapeutic longevity enhancement properties of its combinatorial regenerative biologic candidates.
“We are very excited about this continued collaboration with Lakmus,” said Ira S. Pastor, CEO, Bioquark Inc. “The disciplined development of our combinatorial biologic candidates (Bioquantines) for healthy longevity enhancement, represents another important step in our continued evolution as a company focused on a broad range of therapeutic products and services in the regenerative healthcare space.”
Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.
The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.
“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival, developing a broad understanding of the combinatorial biochemical approaches they use to control nested hierarchies of disease (i.e. gene, cell, tissue, organism, environment),” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This research initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease and degeneration.”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
Artificial Vision, Artificial Retina, Optogenetics, José Alain Sahel MD, CMU RI Seminar
Posted in aging, bioengineering, bionic, biotech/medical, computing, life extension, neuroscience, robotics/AI | Leave a Comment on Artificial Vision, Artificial Retina, Optogenetics, José Alain Sahel MD, CMU RI Seminar
For those interested in life extension and bionic / cyborg type enhancements, this CMU Robotics Institute Seminar gives an overview of the background and current developments in artificial vision. José Alain Sahel MD is a world leading ophthalmologist with a lengthy bio and numerous honors and appointments.
In the future, if you’re going blind, these sight restoration technologies may be used to remediate your vision loss.
Three major ideas are covered. 1) Implanting arrays of tiny 3-color LEDs under a failed retina to stimulate still-okay cells, and 2) using gene therapy to express a novel photoreceptor, borrowed from algae, to restore a form of sight to failed cells. These can be done together. Lots of studies in mice, primates, and humans. Some coverage is also given to 3) directly implanting electronics in the brain to send complete images to vision centers, but this is still at an early stage.
None of this is anywhere near total restoration. The patients can make out a few words for the first time. And unlike normal vision, the range of light intensity levels remains very narrow. But obviously it’s much better than nothing and will get better over time.
As a point of humor, he tells the story of one of his blind patients who totally redesigned one of his experiments for him.
Bioquark Inc. Announces Approval of Bioquantine Food Ingredients in Eurasian Customs Union
Posted in aging, biotech/medical, business, disruptive technology, food, genetics, health, life extension, science, transhumanism | Leave a Comment on Bioquark Inc. Announces Approval of Bioquantine Food Ingredients in Eurasian Customs Union
Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, announced the commercial approval of naturally derived Bioquantine food ingredients in the Eurasian Customs Union (formerly known as the Customs Union of Belarus, Kazakhstan, and Russia). Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, collaborated with Bioquark Inc. on the regulatory approvals.
“We are very excited about this successful regulatory approval,” said Ira S. Pastor, CEO, Bioquark Inc. “The commercialization of Bioquantine food ingredients, including functional foods, drinks, and dietary supplements, represents another important step in our continued evolution as a company focused on a broad range of products and services in the regenerative healthcare space.”
Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.
The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome and virome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.
“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival,” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This Eurasian initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease and degeneration.”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
Link to Press — http://www.prweb.com/releases/2017/01/prweb13955162.htm
Bioquark Inc. (www.bioquark.com) Interview in MoneyWeek
Read whole story: http://moneyweek.com/who-wants-to-live-forever/
10 companies that want to make chemotherapy easier for patients — Bioquark Inc.
Posted in aging, bioengineering, biological, biotech/medical, disruptive technology, DNA, genetics, health, life extension, science | Leave a Comment on 10 companies that want to make chemotherapy easier for patients — Bioquark Inc.
Bioquark Inc. (www.bioquark.com) mention on CNBC — the best way to make chemo easier is to eliminate the need for it forever!
Bioquark Inc. Announces Commercial Cosmetology Relationship with Forest Organics LLC & I-Beauty Charm LLC
Posted in aging, biotech/medical, business, chemistry, disruptive technology, genetics, health, life extension, science | Leave a Comment on Bioquark Inc. Announces Commercial Cosmetology Relationship with Forest Organics LLC & I-Beauty Charm LLC
Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel, natural bio-products for health, wellness and rejuvenation, has entered a collaboration whereby Forest Organics LLC & I-Beauty Charm LLC, a unique, integrated facial and body cosmetology facility, and their state-licensed, highly skilled skin care specialists, will be utilizing novel, natural Bioquantine™ extract complexes as part of their spa procedures, as well as providing consumer access to a range of proprietary skin care products (http://www.forestorganics.life).
“We are very excited about this first company collaboration in the area of beauty care and cosmetology,” said Ira S. Pastor, CEO, Bioquark Inc. “It is another step forward towards the wide applicability of our natural combinatorial bio-products, across a broad range of health and wellness segments, as well as future franchise opportunities.”
The integrated Forest Organics LLC & I-Beauty Charm LLC model was conceived by local Tampa business women, Nadia Goetzinger and Tatyana Reshetnikova, to offer a new generation of products and services related to skin beautification and rejuvenation.
“We look forward to working closely with Bioquark Inc. on this initiative and providing an exclusive range of services and products to customers throughout the greater Tampa metropolitan area,” said Ms. Goetzinger”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biopharmaceutical candidates, as well as non-Rx products for the global consumer health and wellness market segments.
About Forest Organics LLC & I-Beauty Charm LLC
Forest Organics LLC & I-Beauty Charm LLC operate a unique, integrated facial and body cosmetology facility providing novel rejuvenative spa and cosmetology services and products.
Bioquark Inc. and RegenerAge SAPI de CV to Collaborate on Clinical Regenerative Healthcare
Posted in aging, bioengineering, biotech/medical, DNA, health, life extension, neuroscience, posthumanism, science, transhumanism | Leave a Comment on Bioquark Inc. and RegenerAge SAPI de CV to Collaborate on Clinical Regenerative Healthcare
Philadelphia, PA, USA / Mexico City, Mexico — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bioproducts for complex regeneration, disease reversion, and aging, and RegenerAge SAPI de CV, (www.regenerage.clinic/en/) a clinical company focused on translational therapeutic applications of a range of regenerative and rejuvenation healthcare interventions, have announced a collaboration to focus on novel combinatorial approaches in human disease and wellness. SGR-Especializada (http://www.sgr-especializada.com/), regulatory experts in the Latin American healthcare market, assisted in the relationship.
“We are very excited about this collaboration with RegenerAge SAPI de CV,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular and biologic to applications of regenerative and rejuvenative medicine will make for novel and transformational opportunities in a range of degenerative disorders.”
As we close in on $7 trillion in total annual health care expenditures around the globe ($1 trillion spent on pharmaceutical products; $200 billion on new R&D), we are simultaneously witnessing a paradoxical rise in the prevalence of all chronic degenerative diseases responsible for human suffering and death.
With the emergence of such trends including: personalization of medicine on an “n-of-1” basis, adaptive clinical design, globalization of health care training, compassionate use legislative initiatives for experimental therapies, wider acceptance of complementary medical technologies, and the growth of international medical travel, patients and clinicians are more than ever before, exploring the ability to access the therapies of tomorrow, today.
The estimate of the current market size for procedural medical travel, defined by medical travelers who travel across international borders for the purpose of receiving medical care, is in the range of US $40–55 billion.
Additionally, major clinical trial gaps currently exist across all therapeutic segments that are responsible for human suffering and death. Cancer is one prime example. As a leading cause of morbidity and mortality worldwide for many decades, today there are approximately 14 million new cases diagnosed each year, with over 8 million cancer related deaths annually. It is estimated that less than 5% of these patients, take the initiative to participate in any available clinical studies.
“We look forward to working closely with Bioquark Inc. on this exciting initiative,” said Dr. Joel Osorio, Chief of Clinical Development RegenerAge SAPI de CV. “The ability to merge cellular and biologic approaches represents the next step in achieving comprehensive regeneration and disease reversion events in a range of chronic diseases responsible for human suffering and death.”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
About RegenerAge SAPI de CV
RegenerAge SAPI de CV is a novel clinical company focused on translational therapeutic applications, as well as expedited, experimental access for “no option” patients, to a novel range of regenerative and reparative biomedical products and services, with the goal of reducing human degeneration, suffering, and death.